Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 3

Study endpoints associated with treatment methods.

Parameters	EVT group (n = 94)	Bypass group (n = 93)	value
Successful intervention at one month	93 (100)	94 (100)
Direct revascularization	43 (45.7)	47 (50.5)	0.512
Postintervention ABI
One month	0.92 ± 0.1	0.95 ± 0.16	0.113
36 months	0.53 ± 0.16	0.72 ± 0.14	<0.001
Primary patency
12 months	70 (74.5)	76 (81.7)	0.231
24 months	52 (55.3)	62 (66.7)	0.112
36 months	37 (39.4)	55 (59.1)	0.007
Secondary patency
24 months	74 (78.7)	79 (84.9)	0.27
36 months	61 (64.9)	73 (78.5)	0.039
Male	25 (26.6)	31 (33.3)	0.315
AFSR at 36 months	64 (68.1)	71 (76.3)	0.208
LEA at 36 months	32 (34.0)	29 (31.2)	0.954
Major	8 (8.5)	8 (8.6)
Minor	23 (24.5)	21 (22.6)
24-month mortality	15 (16.0)	9 (9.7)	0.199
36-month mortality	27 (28.7)	18 (19.4)	0.134
12-month CAD events	15 (16.0)	17 (18.3)	0.673
24-month CAD events	28 (29.8)	26 (28.0)	0.782
36-month CAD events	30 (31.9)	29 (31.2)	0.914
24-month CVA events	5 (5.3)	10 (10.8)	0.171
36-month CVA events	10 (10.6)	11 (11.8)	0.797
Concomitant medications
Cilostazol treatment
≤3 months	31 (33.0)	23 (24.7)	0.213
>3 months	63 (67.0)	70 (75.3)
Statin treatment	32 (34.0)	42 (45.2)	0.120
Antiplatelet therapy	93 (1001)	94 (100)	1.000

ABI, ankle brachial index; AFSR, amputation-free survival rate; CAD, coronary artery disease; CVA, cerebrovascular accident; EVT, endovascular therapy; LEA, lower-extremity amputation; MALE, major adverse limb event.